FcRn-Targeted Therapies for Autoimmune Disorders | March 23-25 | Virtual Event

Memo

Enhance Our Understanding of FcRn's Biology and MoA to Improve Clinical Success, Maximize its Utility and Novel Therapeutic Applications The neonatal Fc receptor (FcRn) plays a fundamental role in the transcytosis, half-life extension, and recycling of human serum albumin and IgG, however in the case of more than 100+ rare and autoimmune disorders, this can not only be detrimental, but lethal to the health of the individual. Following the high profile JandJ-Momenta deal, UCB's rozanolixizumab expects a Ph3 readout in H1 2021 and Argenx's efgartigimod awaits US filing by the end of 2020, other large players are poised to bring their candidates through the clinic in rapid succession. The digital FcRn-Targeted Therapies for Autoimmune Disorders Summit is not only the first, but the only dedicated meeting that brings you the most up to date clinical and commercial developments utilizing FcRn antagonists in rare and autoimmune diseases. The 3-day program will bring together a wealth of knowledge into the complexities of the FcRn-IgG interaction and the therapeutic strategies which are being employed to yield clinical efficacy. Expect to hear from industry leaders showcasing clinical candidates aimed at disrupting the autoantibody interaction and increasing the clearance of pathogenic IgG from the body. Join 100+ experts online from companies such as CSL Behring, Eli Lilly, Roche, Momenta, Alexion, Argenx and more to discuss FcRn MOA, preclinical model selection and translation, high throughput assays for ligand screening, IgG engineering, and DMPK modelling to ensure best in class medicines are brought to patients. Including an exclusive workshop lead by the FDA who will be exploring protein immunogenicity to better understand FcRn drug development.   URLs:Tickets: https://go.evvnt.com/724981-1?pid=5569 Brochure: https://go.evvnt.com/724981-3?pid=5569  Date and Time: On Tuesday March 23, 2021 at 9:00 am (ends Thursday March 25, 2021 at 4:00 pm) Prices:Conference + 2 Workshops - Pharma and Biotech (Early Booking Rates Available): USD 2697.00,Conference + 1 Workshop - Pharma and Biotech (Early Booking Rates Available): USD 2348.00,Conference Only - Pharma and Biotech (Early Booking Rates Available): USD 1999.00,Conference + 2 Workshops - Solution Providers (Early Booking Rates Available): USD 3297.00,Conference + 1 Workshop - Solution Providers (Early Booking Rates Available): USD 2898.00,Conference Only - Solution Providers (Early Booking Rates Available): USD 2499.00,Conference + 2 Workshops - Academics (Early Booking Rates Available): USD 2397.00,Conference + 1 Workshop - Academics (Early Booking Rates Available): USD 2098.00,Conference Only - Academics (Early Booking Rates Available): USD 1799.00 Speakers: Zuben Sauna, Principal Investigator, OTAT, CBER, U.S. Food and Drug Administration, Dhaval Patel, Executive VP and CSO, UCB, Amita Datta-Mannan, Group Leader, Eli Lilly, Tilman Schlothauer, Senior Principal Scientist, Roche, Jan Terje Andersen, Professor in Biomedical Innovation, University of Oslo, Armin Sepp, Scientific Leader and GSK Fellow, Early Pre-Clinical DMPK Modelling, GSK, Sally Ward, Director of Translational Immunology and Professor of Molecular Immunology, University of Southampton, Anne Verhagen, Senior Director and Head of Biochemistry, CSL Research, Amit Choudhary, Associate Director, Momenta, Ken Howard, Associate Professor, Head of Bioengineered Drug Designs Laboratory, Aarhus University, Richard Blumberg, Professor of Medicine, Harvard Medical School, Wayne Lencer, Chief and Longwood Chair in Paediatrics, Harvard Medical School, Bruno Sarmento, Principal Investigator, Nanomedicine and Translational Drug Delivery, INEB - Instituto de Engenharia Biomedica, Brandon Dekosky, Assistant Professor, Pharmaceutical Chemistry, University of Kansas, Jordan Dimitriov, Scientist, Department of Immunology, INSERM-Centre de Recherche des Cordeliers, Anthony Shock, Director, UCB, Javier Blanco, Professor, Pharmaceutical Sciences, University at Buffalo, Daniel Lagasse, Biologist, DPPT, OTAT CBER, U.S. Food and Drug Administration, Sebastien Lacroix-Desmazes, Scientist, Protein Therapeutics, Centre National de la Recherche Scientifique, Ashley St. John, Associate Professor, Emerging Infectious Diseases, Duke-NUS Medical School, Peter Ulrichts, Scientific Lead, Neuromuscular Franchise, Argenx, Alan Lazarus, Professor of Medicine, University of Toronto